Richard H. Tullis Resigns as Vice President of Aethlon Medical, Inc
February 17, 2016 at 02:04 am IST
Share
On February 9, 2016, Mr. Richard H. Tullis, entered into a part-time consulting agreement with Aethlon Medical, Inc. Mr. Tullis will retain his title of Chief Science Officer and will continue to provide services under the terms of a Consulting Agreement with the company. In connection with the change in his employment, Mr. Tullis resigned as its Vice President.
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies.